LOSARTAN POTASSIUM TABLETS MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2025 - 2032)

Global Losartan Potassium Tablets Market Size and Forecast – 2025 to 2032

The global losartan potassium tablets market is estimated to be valued at USD 2.64 Bn in 2025 and is expected to reach USD 4.13 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 6.6% from 2025 to 2032. This steady growth reflects increasing prevalence of hypertension and cardiovascular diseases worldwide, along with expanding access to affordable medication in emerging markets, which collectively drive demand for losartan potassium tablets.

Key Takeaways of the Global Losartan Potassium Tablets Market

• The 25 mg segment is projected to account for 50.1% of the global losartan potassium tablets market share in 2025.
• Hypertension segment is expected to capture 60.8% of the market share in 2025.
• Adult segment is projected to hold 43.2% of the losartan potassium tablets market share in 2025.
• North America is expected to lead the market, holding a share of 41.3% in 2025. Asia Pacific is anticipated to be the fastest-growing region, with a market share of 24.5% in 2025.

Market Overview

In terms of market trends, there is a noticeable shift towards the development of novel formulations and fixed-dose combinations that enhance patient compliance and therapeutic efficacy. Additionally, rising awareness regarding cardiovascular health and improved diagnostic capabilities are fueling early intervention, boosting losartan adoption. The market also witnesses increased competition from generic manufacturers, leading to competitive pricing and wider availability, which further contributes to the market expansion during the forecast period.

Current Events and Its Impact

Uncover macros and micros vetted on 75+ parameters: Get instant access to report

Segmental Insights

To learn more about this report, Download Free Sample

Losartan Potassium Tablets Market Insights, By Strength - 25 mg Contributes the Highest Share of the Market Owing to its Favorable Balance Between Efficacy and Patient Tolerability

In 2025, the 25 mg segment is expected to dominate the market, accounting for 50.1% of the market share. It is all due to the fact that this strength is perfectly positioned to be the first choice in hypertension treatment. The doctors usually go for the lower 25 mg dose and monitor the patient's response to the treatment closely while also reducing the risk of side effects. This cautious approach to dosing is extremely important for those patients who either have just been diagnosed or are sensitive to blood pressure medications, hence, 25 mg has become the leading initial strength.

For example, Zydus Cadila, based in Ahmedabad, India, is a major pharmaceutical company recognized for its strong presence in generics and specialty formulations. The firm’s Losartan Potassium Tablets (25mg, 50mg, 100mg) and Losartan Potassium + Hydrochlorothiazide Tablets (50/12.5mg, 100/25mg) treat hypertension and help prevent stroke.

Losartan Potassium Tablets Market Insights, By Indication - Hypertension Dominates the Market Driven by Widespread Prevalence and Primary Use of Losartan in Blood Pressure Management

The hypertension segment is projected to hold 60.8% of the market share in 2025. This segment is still the most significant indication for losartan potassium tablets, reflecting the global burden of this chronic condition. Losartan's efficacy in lowering vascular resistance and controlling high blood pressure has been established and it is used as a frontline therapy.

Moreover, Losartan is sometimes listed as the best angiotensin receptor blocker for its safe use and ability to protect the kidneys. In clinical practice, managing hypertension effectively with Losartan reduces the risk of severe cardiovascular events such as stroke, myocardial infarction, and heart failure.

Losartan Potassium Tablets Market Insights, By Age Group - Adult Patients Contribute the Highest Share due to the Prevalence of Hypertension and Better Clinical Trial Support for this Demographic

The adult segment is projected to hold 43.2% of the market share in 2025, due to this segment being the main consumer of losartan potassium tablets, which is a direct result of the growing hypertension occurrence among the middle-aged and elderly people. Hypertension is commonly experienced by people of 40 years and above, who are also suffering from risk factors like lack of physical activity, poor nutrition, and stress, thus, they are the ones who need drugs the most.

U.S. FDA approval and extensive clinical trial data have mostly included adults, which in turn, has made doctors confident in prescribing this drug to adult patients. Regulatory approvals and treatment guidelines predominantly address dosing, efficacy, and safety parameters in adults, further driving usage in this age group.

Regional Insights

To learn more about this report, Download Free Sample

North America Losartan Potassium Tablets Market Analysis and Trends

The global losartan potassium tablets market has its major player in North America, which has already secured an estimated 41.3% of the market share in 2025. North America's losartan potassium tablets market leadership position is supported by a robust pharmaceutical industry, characterized by a comprehensive healthcare infrastructure, and government interventions that are favorable to the management of chronic diseases. Drug quality and safety regulations are advantageous to the region and are complemented by the pharmaceutical industry investments in R&D, which are also quite significant.

The presence of top-notch pharmaceutical companies such as Pfizer, Teva Pharmaceuticals, and Mylan (now under Viatris) not only guarantees the quality and safety of the drugs sold in the market but also drives innovation in drug formulation. Furthermore, the public's high awareness of hypertension and cardiovascular diseases combined with the availability of insurance motivates the consistent demand for losartan potassium and other antihypertensive medications.

Asia Pacific Losartan Potassium Tablets Market Analysis and Trends

With an estimated market share of 24.5% in 2025, the Asia Pacific region emerges as the fastest growing market for losartan potassium tablets, with the increase in the incidence of hypertension and the opening up of healthcare access in countries like China and India, Japan, and the other Southeast Asian nations acting as the main growth drivers. Governments are undertaking initiatives to provide medicines at affordable prices and increasing the coverage of health insurance, which is acting as a catalyst in the market penetration process.

The sheer size of the population and the growing number of people in the middle class are supporting the demand for the product to a great extent. Besides, the growth of the market is accelerated by the increasing presence of both multinationals (like Novartis and Lupin) and domestic pharmaceutical companies, who are taking advantage of inexpensive manufacturing and local distribution networks.

Losartan Potassium Tablets Market Outlook for Key Countries

U.S. Losartan Potassium Tablets Market Analysis and Trends

The U.S. losartan potassium tablets market is marked by state-of-the-art healthcare infrastructure and strict regulatory supervision by the U.S. FDA, which assures the quality of losartan potassium tablets through high standards. Major players in the market like Pfizer and Viatris, who are mainly responsible for drug innovation and large distribution networks, have a strong presence in this area. Apart from this, the U.S. also witnesses active generic competition that affects the market and makes treatment options cheaper and easier to access for the patients.

For example, Teva Pharmaceuticals USA, Inc., a major U.S. division of global generic drug leader Teva Pharmaceutical Industries, expanded its voluntary nationwide recall of Losartan Potassium Tablets 50 mg and 100 mg, which were sold exclusively to Golden State Medical Supply, Inc., after detecting an impurity called NMBA at levels above FDA limits, with a small potential cancer risk for patients exposed long term to affected batches.

China Losartan Potassium Tablets Market Analysis and Trends

The market for losartan potassium tablets in China is very quickly growing due to the government's commitment to chronic disease management and providing affordable healthcare. Local manufacturers such as Jiangsu Hengrui Medicine and Beijing Novartis Pharma have been very helpful in the process of bringing high-quality generic and branded versions of losartan tablets to the market, thereby helping in the availability of the product in the country. The government's efforts to advance healthcare and increase reimbursements for antihypertensive drugs are the primary drivers behind the skyrocketing consumption.

In October 2024, the company, Zhejiang Tianyu Pharmaceutical (300702.SZ), reported that its wholly-owned subsidiary, Nuode Pharmaceutical, received a new drug registration certificate from the National Medical Products Administration for a new specification of Losartan Potassium + Hydrochlorothiazide tablets, intended for hypertension combination therapy.

India Losartan Potassium Tablets Market Analysis and Trends

India keeps on being a major center for the world market of losartan potassium tablets; the companies producing and exporting them are Lupin, Sun Pharmaceutical, and Dr. Reddy’s Laboratories. The country is also a significant market for the drug because of its large population and increasing cases of hypertension. Access to essential medicines is being improved through government programs while the measures to speed up the approval process for generic drugs are also making the market bigger. Moreover, attractive pricing, along with effective supply chains, ensures that both rural and urban areas can be reached

For example, Cipla Ltd. manufactures losartan potassium tablets as part of its antihypertensive therapy line and exports to over 80 countries. Glenmark Pharmaceuticals produces losartan formulations targeting both domestic and African markets through its branded generics portfolio. Aurobindo Pharma supplies losartan potassium and its combinations to regulated markets including the U.S., the EU, and WHO-prequalified programs.

Germany Losartan Potassium Tablets Market Analysis and Trends

The Germany market for losartan potassium tablets in Europe is still the largest because of the combination of strict healthcare regulations and the presence of efficient healthcare reimbursement systems. Companies like Bayer and Stada Arzneimittel are major players in the market, mainly doing so by providing high-quality production and by marketing and supplying both branded and generic losartan potassium tablets. The pharmaceutical R&D sector in Germany is very strong and helps drugs to be manufactured with better therapeutic effects and patients' compliance.

For example, Ratiopharm GmbH, part of the Teva Group, distributes generic losartan potassium tablets across Germany’s retail pharmacies. Zentiva Deutschland GmbH markets losartan and combination therapies as cost-effective cardiovascular options. Mylan Germany (now part of Viatris) offers multiple dosage strengths of losartan under its antihypertensive product portfolio.

End User Feedback and Unmet Needs in the Losartan Potassium Tablets Market

• A consistent blood pressure measure, which is the main reason for prescribing the drug, has contributed to the positive image of Losartan Potassium tablets among healthcare professionals and patients. Good tolerability and wide availability are other factors that led to the acceptance of the product. The long-term use of the drug in management of hypertension and its effect when combined with hydrochlorothiazide, in such cases, stable outcomes are achieved with fewer side effects, are some of the reasons why the end users are still giving it a thumbs up.
• On the other hand, issues of quality and availability of the product in some unbranded markets are still of concern to patients. Also, the patients' powerlessness due to lack of a proper formulation, unclear labelling, and high cost are some things they mention. These unmet needs when addressed can actually make the drug trustable, thus foster brand loyalty and also give room for new products in the competitive antihypertensive market.

Market Players, Key Developments, and Competitive Intelligence

To learn more about this report, Download Free Sample

Key Developments

• In April 2025, Scienture LLC. a U.S.-based pharmaceutical company listed on NASDAQ as SCNX, announced its manufacturing and supply chain readiness for the upcoming July 2025 launch of Arbli (Losartan Potassium Tablets) Oral Suspension, 10 mg/mL. Its subsidiary, Scienture LLC, initiated production through contract partner Saptalis Pharmaceuticals LLC, which confirmed readiness to supply commercial batches on schedule.
• In February 2023, Granules India Limited, a Hyderabad, India-based pharmaceutical company, received U.S. FDA approval for its Abbreviated New Drug Application (ANDA) for Losartan Potassium Tablets USP in 25 mg, 50 mg, and 100 mg strengths. The product is bioequivalent to Cozaar Tablets by Organon LLC and is indicated for treating hypertension in adults and pediatric patients aged six years and above. With this approval, Granules India reached a total of 54 U.S. FDA-approved ANDAs, including 52 final and 2 tentative.

Top Strategies Followed by Global Losartan Potassium Tablets Market Players

• The major players in the market are putting money into R&D with the aim of more and more new losartan forms, which are the bioavailability-caused tablets, extended release, and fixed-dose combos intended for a certain patient group, R&D. They also have OEM/CMO partnerships for process optimization, tech transfer, and dual-sourcing so that they have the capacity, quality, and compliance secure. This ends up with lower unit cost, faster scale-up and approvals, stronger tender positioning, and tighter control of supply risk
  • Sun Pharma, Dr. Reddy’s Laboratories, and Lupin develop advanced losartan formulations such as extended-release and fixed-dose combinations, supported by strong CMO partnerships for scale and compliance. Teva Pharmaceuticals and Sandoz (Novartis) also leverage dual-sourcing and global manufacturing to ensure quality and cost efficiency.

• Mid-level players in the losartan potassium tablets market are in a competitive niche where quality and affordability are equitably balanced. These manufacturers are mainly in price-sensitive regions or in developing countries where healthcare budgets are constrained selling their cost-effective products. To keep quality up while making production cheaper, the mid-tier players often cooperate with technology providers and contract manufacturers, who allow them to become efficient and improve their operating capacities.
  • Glenmark, Torrent, Aurobindo, and Alembic focus on cost-effective losartan tablets for developing regions, using tech collaborations and integrated production to balance price and quality. Hetero and Cadila strengthen their presence through hospital and government tender supply.

• The global losartan potassium tablets market has been characterized by small-scale players who have been able to find their way around targeting certain sub-niches or using innovation as a means of creating specialized formulations aimed at specific therapeutic advantages. Cutting-edge technologies such as novel drug delivery systems, personalized medicine approaches or advanced excipient combinations have been adopted by these smaller companies to ensure they remain competitive even with limited resources.
  • Micro Labs, Unichem, and Intas target niche formulations and improved drug delivery designs. Alkem explores novel excipients for enhanced efficacy, while Zentiva and Berlin-Chemie Menarini innovate in specialized losartan variants within Europe.

Market Report Scope

Losartan Potassium Tablets Market Report Coverage

Losartan Potassium Tablets Market Dynamics

To learn more about this report, Download Free Sample

Losartan Potassium Tablets Market Driver - Rising Prevalence of Hypertension and Cardiovascular Disorders

One of the main causes of the increasing global demand for losartan potassium tablets is the rising number of hypertension and heart diseases. Losartan, along with other angiotensin II receptor blockers (ARBs), is a major drug in the treatment of hypertension and the prevention of its associated complications like stroke, heart attack, and kidney damage. The growing prevalence of lifestyle-related risk factors such as poor diet, lack of exercise, obesity, and stress has led to an increase in hypertension, thus, expanding the potential patient market for Losartan therapy.

In September 2025, the World Health Organization (WHO), the leading global health agency, reported that an estimated 1.4 billion adults aged 30–79 years about one-third of the global population in this age group had hypertension in 2024, with two-thirds living in low- and middle-income countries. Around 600 million adults remain unaware of their condition, while only 23% of patients have their blood pressure under control.

Losartan Potassium Tablets Market Opportunity - Development of Combination Therapies with Diuretics or Calcium Channel Blockers

The primary factor behind the global losartan potassium tablets market growth could be the development and introduction of combination therapies with losartan potassium and diuretics or calcium channel blockers already being explored or developed. The global losartan potassium tablets market is characterized by the presence of multiple players offering diverse products, however, the majority of sales are covered by monotherapies.

In March 2020, the American Academy of Family Physicians (AAFP) reported that over 70% of adults with hypertension need at least two drugs for control. The study advised combining classes like thiazide diuretics, calcium channel blockers, ACE inhibitors, or ARBs such as Losartan Potassium Tablets to achieve faster and more effective blood pressure reduction, especially in patients with severe hypertension or chronic conditions.

Analyst Opinion (Expert Opinion)

• The losartan potassium tablets market is growing steadily due to the rising burden of hypertension, expanding generic drug use, and government support for affordable cardiovascular care. Advancements in formulation technology and improved healthcare access in developing regions are further driving adoption. However, pricing pressure, raw material constraints, and strict regulatory norms remain key challenges, while emerging economies offer strong growth opportunities.
• Recent discussions at the American Heart Association Scientific Sessions, European Society of Cardiology Congress, and World Hypertension Congress have highlighted innovations in antihypertensive therapy. Programs such as the FDA’s Generic Drug Initiative and India’s Jan Aushadhi scheme are improving access to cost-effective losartan treatments. Collaborative healthcare policies and new distribution models are expected to strengthen market presence globally.

Market Segmentation

• Strength Insights (Revenue, USD Bn, 2020 - 2032)
  • 25 mg
  • 50 mg
  • 100 mg
• Indication Insights (Revenue, USD Bn, 2020 - 2032)
  • Hypertension
  • Hypertensive Patients with Left Ventricular Hypertrophy (LVH)
  • Type 2 Diabetes with Nephropathy
• Age Group Insights (Revenue, USD Bn, 2020 - 2032)
  • Adult
  • Pediatric
  • Geriatric
• Type Insights (Revenue, USD Bn, 2020 - 2032)
  • Branded
  • Generic
• Formulation Type Insights (Revenue, USD Bn, 2020 - 2032)
  • Immediate-Release Tablets
  • Extended-Release Tablets
• Packaging Type Insights (Revenue, USD Bn, 2020 - 2032)
  • Blister Packs
  • Bottles
  • Strip Packs
• Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• End User Insights (Revenue, USD Bn, 2020 - 2032)
  • Hospitals
  • Clinics
  • Ambulatory Surgical Centers
  • Homecare Settings
• Regional Insights (Revenue, USD Bn, 2020 - 2032)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa
• Key Players Insights
  • Merck (MSD)
  • Teva Pharmaceutical Industries
  • Torrent Pharmaceuticals
  • Sun Pharmaceutical Industries
  • Reddy’s Laboratories
  • Aurobindo Pharma
  • Lupin Limited
  • Zydus Lifesciences
  • Alembic Pharmaceuticals
  • Viatris (Mylan)
  • Apotex Inc.
  • Hikma Pharmaceuticals
  • Cipla Limited
  • Sandoz (Novartis Division)
  • Intas Pharmaceuticals

Sources

Primary Research Interviews

Industry Stakeholders List

• Pharmaceutical formulation scientists
• API manufacturers and suppliers
• Regulatory affairs specialists
• Quality assurance managers
• Hospital procurement officers
• Drug wholesalers and distributors

End Users List

• Cardiologists
• Nephrologists
• General practitioners
• Retail pharmacists
• Hospital pharmacists
• Hypertensive patients

Government and International Databases

• U.S. Food and Drug Administration (FDA)
• European Medicines Agency (EMA)
• World Health Organization (WHO)
• Pharmaceuticals and Medical Devices Agency (PMDA, Japan)
• Central Drugs Standard Control Organization (CDSCO, India)
• National Institutes of Health (NIH)

Trade Publications

• Pharmaceutical Technology
• Drug Development & Delivery
• Pharma Manufacturing
• Contract Pharma
• In-Pharma Technologist
• Chemical & Engineering News

Academic Journals

• The Lancet
• Journal of Hypertension
• British Journal of Clinical Pharmacology
• International Journal of Cardiology
• European Journal of Pharmaceutical Sciences
• Clinical Therapeutics

Reputable Newspapers

• The Wall Street Journal
• Financial Times
• The New York Times
• Reuters Health
• The Guardian Health
• Bloomberg

Industry Associations

• International Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
• Indian Pharmaceutical Association (IPA)
• American Pharmacists Association (APhA)
• European Federation of Pharmaceutical Industries and Associations (EFPIA)
• Biotechnology Innovation Organization (BIO)
• World Self-Medication Industry (WSMI)

Public Domain Resources

• MedlinePlus
• PubMed Central
• OpenFDA Data Portal
• World Bank Health Data

Proprietary Elements

• CMI Data Analytics Tool: Proprietary analytics tool to analyze real-time market trends, consumer behavior, and technology adoption in market
• Proprietary CMI Existing Repository of Information for Last 8 Years